


61. (New) A compound having a Formula I:



wherein


A^2 is a single or fused ring, each ring constituting A^2 is an aliphatic or aromatic ring which may have at least one hetero atom, each ring constituting A^2 may be substituted by at least one group selected from halogen, hydroxy, alkyl, cycloalkyl, alkoxy, perfluoroalkyl, perfluoroalkoxy, cyano, nitro, mercapto, acyl, amino, acylamino and aryl,

M^1 is alkylene which may be substituted by halogen, hydroxy, $(\text{C}_1\text{-C}_5)$ alkyl, and / or $(\text{C}_1\text{-C}_5)$ alkoxy,


B is alkyl, cycloalkyl, aryl, arylalkyl, hydroxyarylalkyl, aryloxyarylalkyl or arylalkoxyalkyl,

R is hydrogen, alkyl, or cycloalkyl,

D is



or





wherein

R^1 is hydrogen, alkyl, or cycloalkyl, and


R^2 and R^3 are independently hydrogen, alkyl, hydroxyl alkyl, arylalkyl which may be substituted on its aromatic ring, or arylalkoxyalkyl which may be substituted on its aromatic ring, acyl, amidino, alkoxy carbonyl, or either R^2 or R^3 can be taken together with R^1 to form alkylene, and

R^2 and R^3 can be taken together with the nitrogen atom to which R^2 and R^3 are bonded to form a heterocycle, and

M^2 is :



or



wherein

x, y and z are independently an integer of 0 to 4, and

R^5 , R^6 , R^7 and R^8 are independently hydrogen, halogen, alkyl, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-NHC(O)R^9$, $-C(O)OR^9$, $-OCOR^9$, $-OC(O)OR^9$, $-CONR^9R^{10}$, or can be taken together with R^1 or R^2 and the bridging group which links R^5 , R^6 , R^7 or R^8 to R^1 or R^2 to form a carbocycle or heterocycle,

R^9 and R^{10} are independently hydrogen or alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene,

R^5 and R^7 , or R^6 and R^8 can be taken together with the carbon atoms to which R^5

and


R^7 , or R^6 and R^8 are bonded to form a carbocycle or heterocycle, or

R^5 and R^6 , or R^7 and R^8 can be taken together with the carbon atom to which R^5 and R^6 , or R^7 and R^8 are bonded, respectively, to form carbonyl, thiocarbonyl or imino, and

E is oxygen atom or sulfur atom,

and pharmaceutically acceptable salts and individual isomers thereof.

62. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein A^2 is :



wherein

A^3 is a 5, 6, or 7 membered

aromatic ring which may include at

least one hetero atom, and may be substituted by a group selected from halogen, hydroxy, (C_1-C_5) alkyl, (C_1-C_5) alkoxy, (C_1-C_5) perfluoroalkyl, (C_1-C_5) perfluoroalkoxy, nitro, cyano, mercapto, amino, acylamino, acyl and / or phenyl, or

A^3 can be fused with at least 5 to 8 membered aliphatic or aromatic ring which may include at least one hetero atom, and

l is 0, 1, or 2, and

X is $-CH_2-$, $-O-$, $-S(O)r-$, $-C(O)-$, $-C(S)-$, $-CH=CH-$, $-CH(OH)-$, or $-NR^4-$, and

R^4 is hydrogen, (C_1-C_5) alkyl, (C_3-C_8) cycloalkyl, acyl, or alkoxy carbonyl, and


m is 0, 1, or 2, and

Y is $-C(O)-$, $-C(S)-$, or (C_1-C_5) alkylene which may be substituted by (C_1-C_5) alkyl,

p is 0, 1, or 2, and

r is 0, 1, or 2, and


Z is substituted or unsubstituted (C_1-C_5) alkylene, $-NR^4-$, or



wherein

A^4 is a 5 or 6 membered aromatic ring which may be comprised of at least one hetero atom, and

A⁴ may be substituted by a group selected from halogen, hydroxy, (C₁-C₅) alkyl, (C₁-C₅)alkoxy, (C₁-C₅)perfluoroalkyl, (C₁-C₅)perfluoroalkoxy, nitro, cyano, amino, acylamino and/or phenyl, or



wherein

G₁ and G₂ are independently carbon or nitrogen, and

one of --- may represent double bond when either G₁ and G₂ or G₂ and G₃ are carbon, and

G₃, G₄, and G₅ are independently -O-, -S(O)_r-, -C(O)-, -C(S)-, -CH=CH-, -CH(OH)-, -NR⁴-, or (C₁-C₅)alkylene,

r is 0, 1, or 2, and

n is 0 or 1.

63. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein A² is selected from :

10,11-Dihydrodibenzo[b,f][1,4]oxazepin-11-one,

3,4-Dihydro-2H-quinoline,

2-Oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocine,

2,3-Dioxo-2,3-dihydro-indole,

2-Oxo-3,4-dihydro-2H-quinoline,

3-Oxo-2,3-dihydro-pyrido[3,2-b][1,4]oxazine,

4-Methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepine,

2,3-Dihydro-1H-pyrrolo[2,1-c] [1,4]benzodiazepin-5,11(10H,11aH)-dione,
3-Oxo-2,3-dihydro-benzo[1,4]thiazine,
6-Oxo-11,12-dihydro-6H-dibenzo[b,f]azocine,
2-Oxo-2,3,4,5-tetrahydrobenzo[b]azepine,
1,1,4-Trioxo-2,3-dihydro-benzo[1,5]thiazepine,
4-Oxo-2,3-dihydro-1,5-benzothiazepine,
5,11-Dihydro-dibenzo[b,e]azepine,
5H-Dibenzo[b,e]azepin-6,11-dione,
5H-Dibenzo[b,f]azocin-6-one,
10H-Dibenzo[b,f][1,4]thiazepin-11-one,
5-Oxo-5,10H-dibenzo[b,f][1,4]thiazepin-11-one,
5,5-Dioxo-5,10H-dibenzo-[b,f][1,4]thiazepin-11-one,
4-Oxo-2,3-dihydro-[1,5]benzoxazepine,
6,12-Dioxo-6,6a,7,8,9,10-exahydro-12H-benzo[e]-pyrido[1,2-a][1,4]diazepine,
2-Oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrole and
phenothiazine, each of which may be substituted.

64. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein :

B is phenylalkyl, naphthylalkyl, 5,6,7,8-tetrahydro-naphthylalkyl, indolylalkyl, quinolylalkyl, or phenylalkoxyalkyl, which may be substituted by a group selected from halogen, hydroxy, (C₁-C₅)alkyl, (C₁-C₅)alkoxy, nitro, cyano, amino, amino, phenyl, or phenyl.

65. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 61 wherein:

R^1 is hydrogen, (C_1-C_5) alkyl, (C_3-C_8) cycloalkyl, (C_1-C_5) hydroxyalkyl, or (C_1-C_5) aminoalkyl, and

R^2 and R^3 are independently hydrogen, (C_1-C_5) alkyl, (C_1-C_5) alkyl, (C_1-C_6) acyl, or (C_1-C_6) alkoxycarbonyl, and
















R^1 and R^2 or R^2 and R^3 are can be taken together to form alkylene,
















R^5 , R^6 , R^7 , and R^8 are independently hydrogen, halogen, (C_1-C_5) alkyl, (C_1-C_5) alkyl, $-OR^9$, $-SR^9$, $-NR^9R^{10}$, $-OC(O)OR^9$, $-NHC(O)R^9$, $-C(O)OR^9$, and R^5 can be taken together with R^1 or R^2 to form alkylene,


R^9 and R^{10} are independently hydrogen, (C_1-C_5) alkyl, and

R^9 can be taken together with R^1 or R^2 to form alkylene.

66. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 65 wherein D is selected from:







or

67. (New) A compound selected from:

N-(2-Aminoethyl)-3-phenyl-2(R)-[2-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;

Sub
E1

3-(3-Acetylamino-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)-N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]propionamide;
N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;
N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;
N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;
N-(4-Aminobutyl)-3-(naphthalen-2-yl)-2(R)-[2-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-acetylamino]propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H-(11aS)-pyrrolo[2,1-c][1,4]benzodiazepin-10-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;
N-[1(R)-(4-Aminobutylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-methyl-2,5-dioxo-2,3,4,5-tetrahydro-benzo[e][1,4]diazepin-1-yl)propionamide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[3,2-b][1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-oxo-2,3-dihydro-benzo[1,4]oxazin-4-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

N-(2-Amino-2-methylpropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(3-oxo-2,3-dihydro-benzo[1,4]thiazin-4-yl)butyramide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Methylamino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[(3-Aminopropyl)-methylcarbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)-propionylamino]propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-

dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(2-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-(1(R)-[Bis-(3-aminopropyl)carbamoyl]-2-(naphthalen-2-yl)ethyl)-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,1,4-trioxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-phenothiazin-10-yl-propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-11,12-dihydro-6H-dibenzo[b,f]azocin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)2(R)-[3-(2-oxo-2,3,4,5-tetrahydro-benzo [b]azepin-1-yl)propionylamino]propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(2-oxo-3,4,5,6-tetrahydro-2H-benzo [b]azocin-1-yl)propionylamino]propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(2-aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(1H-indol-3-yl)-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(5,6,7,8-tetrahydro-naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]oxazepin-10-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(1,4-dioxo-2,3-dihydro-[1,5] benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2-methyl-4-oxo-2,3-dihydro[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3-dihydro-1H,(11aS)-pyrrolo[2,1-c][1,4]diazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(phenothiazin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(6-methoxy-2-oxo-2,3,4,5-tetrahydro-benzo[b]azepin-1-yl)butyramide;

N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalene-2-yl)ethyl]-3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-(3-Amino-2-hydroxypropyl)-3-(naphthalene-2-yl)-2(R)-[3-(4-oxo-7-trifluoromethyl-

2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)butyramide;
N-(3-Amino-2-hydroxypropyl)-3-(naphthalen-2-yl)-2(R)-[3-(4-oxo-2,3-dihydro-[1,5]-benzoxazepin-5-yl)propionylamino]propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide;
N-(3-Amino-2-hydroxypropyl)-2(R)-[3-(8-fluoro-4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)propionylamino]-3-(naphthalen-2-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(8-fluoro-4-oxo-[1,5]benzothiazepin-5-yl)butyramide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6-oxo-6,11-dihydro-dibenzo[b,e]-azepin-5-yl)propionamide;
N-[1(R)-(2-Aminoethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo[b,e]azepin-5-yl)propionamide;
N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,11-dioxo-6,11-dihydro-dibenzo-[b,e]-azepin-5-yl)propionamide;
N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(6-oxo-6H-dibenzo[b,f]azocin-5-yl)pentanamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(11-oxo-11H-dibenzo[b,f][1,4]-thiazepin-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,11-dioxo-5,11-dihydrodibenzo-[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-5-(5,5,11-trioxo-5,11-dihydro-dibenzo[b,f][1,4]thiazepin-10-yl)pentanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(2,2-dimethyl-4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(7-chloro-5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(6,12-dioxo-6,6a,7,8,9,10-hexahydro-12H-benzo[e]pyrido[1,2-a][1,4]diazepine-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(9-fluoro-2-oxo-3,4,5,6-tetrahydro-2H-benzo[b]azocin-1-yl)propionamide;

N-[1(R)-(3-Aminopropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]-thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-2H-benzo[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-amino-2(S)-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-amino-2(R)-hydroxy-propylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-4-(4-oxo-3,4-dihydro-[1,5]-benzothiazepin-5-yl) butanamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(5,11-dioxo-2,3,11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepine-10-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2,2-dimethyl-3-(1,1,4-trioxo-benzo-[1,5]thiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-ethylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-2-methyl-3-(4-oxo-3,4-dihydro-[1,5]benzothiazepin-5-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(4-oxo-3,4-dihydro[1,5]benzothiazepin-5-yl)butyramide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(3-cyano-5-isopropyl-2-oxo-2H-cyclohepta-4,6,8-trieno[b]pyrrol-1-yl)propionamide;

N-[1(R)-(3-Amino-2-hydroxypropylcarbamoyl)-2-(naphthalen-2-yl)ethyl]-3-(5,11-dioxo-2,3, 11,11a-tetrahydro-1H,5H-benzo[e]pyrrolo[1,2-a][1,4]diazepin-10-yl)propionamide;

and

N-[1(R)-[2-Hydroxy-3-(2(R)-hydroxypropylamino)propylcarbamoyl]-2-naphthalen-2-yl-ethyl]-4-(4-oxo-2,3-dihydro-[1,5]benzothiazepin-5-yl)butyramide.

68 (New) A composition which comprises an inert carrier and a compound according to claim 61.

69. (New) A composition which comprises an inert carrier, a compound according to claim 61 and at least one of the following components:

Sub
E1
a growth hormone secretagogues selected from KP-102(GHRP-2),GHRP-6, Hexarelin, GHRP-1, L-692,429, L-692,585, MK-0677 and G-7220,

or
a growth hormone releasing factor (GRF) selected from IGF-1, IGF-2 and B-HT920, and a growth hormone.

70. (New) A method for increasing levels of endogenous growth hormones in a human or an animal which comprises administering to such human or animal an effective amount of a compound according to claim 61.

71. (New) A method for treating diseases or conditions which may be treated by growth hormone which comprises administering to a human or an animal of such treatment an amount of a compound according to claim 61 which is effective in promoting release of said growth hormone.

72. (New) A method of claim 71 wherein the disease or condition is selected from the group consisting of osteoporosis; catabolic illness; immune deficiency, hip fracture; musculoskeletal impairment in the elderly; growth hormone deficiency in adults or in children; obesity; cachexia and protein loss due to chronic illness and treatment of patients recovering from major surgery, wounds and burns.

73. (New) A method for increasing the level of growth hormone in a human or an animal which comprises administering to a human or animal a compound according to claim 61 in combination with any one of the following components:


an additional growth hormone secretagogue selected from KP-102(GHRP-2), GHRP-6, Hexarelin and GHRP-1, a growth hormone releasing factor(GRF) selected from IGF-1, IGF-2 and B-HT920, and a growth hormone.

74. (New) A method for the treatment of osteoporosis which comprises administering to a patient with osteoporosis a combination of a bisphosphonate compound and a compound according to claim 61.


75. (New) A method for the treatment of bone fractures, wounds or burns which comprises administering to a patient with bone fractures, wounds or burns a combination of fibroblast growth factor (FGF) or platelet-derived growth factor (PDGF) and a compound of claim 61.

76. (New) A method to increase the rate and extent of growth of animals, to increase the milk or wool production of animals the method comprising administering to a subject in need thereof an effective amount of a compound according to claim 61.


77. (New) A process for the preparation of a compound of claim 61 which comprises reacting a compound having a formula:



wherein R^{11} is a leaving group with a compound having a formula:





78. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 61 wherein D is selected from:




79. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 61 wherein R is hydrogen.

80. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 62 wherein A² is selected from:



















81. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 79 wherein M^1 is selected from:




82. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to Claim 79 wherein B is alkyl, substituted alkyl, cycloalkyl, substituted cycloalkyl, or aryl, arylalkyl or arylalkoxyalkyl which may be substituted on their aromatic ring.









83. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 81 wherein D is selected from:







84. (New) A compound, and pharmaceutically acceptable salts and individual isomers thereof according to claim 81 wherein D is selected from:



and

